Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma.

@article{Eltabbakh2000ExtremeDR,
  title={Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma.},
  author={Gamal H Eltabbakh},
  journal={Journal of surgical oncology},
  year={2000},
  volume={73 3},
  pages={148-52}
}
BACKGROUND AND OBJECTIVES The extreme drug resistance (EDR) assay is an in vitro chemoresistance assay performed on tumor samples grown in culture and is claimed to predict drugs unlikely to produce response. Its clinical value in patients with epithelial ovarian cancer (EOC) has recently been questioned. The aim of this study is to describe EDR assay results and responses to chemotherapy among women with primary peritoneal adenocarcinoma (PPA) and to compare them with those of women with EOC… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
Fresh tumor specimens from 20 consecutive women with PPA were tested for EDR to the following drugs : cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan .
There was no significant difference in the incidence of EDR to cisplatin , carboplatin , paclitaxel , doxorubicin , cyclophosphamide , ifosfamide , etoposide , hexamethylmelamine , and topotecan among patients with PPA and those with EOC .
All Topics